In patients with irritable bowel syndrome (IBS), the probiotic Bifidobacterium longum (Bf) NCC3001 not only alleviates gastrointestinal symptoms but also depression, according to results from a double-blind, placebo-controlled trial.
The evidence of activity from oral intake of the probiotic in the central nervous system (CNS) was reinforced by changes on functional MRI (fMRI) relative to baseline and placebo.
“Our results demonstrate that six-week treatment with Bf NCC3001 improves